Last reviewed · How we verify
L-Tretoquinol — Competitive Intelligence Brief
phase 2
tretoquinol
Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Thromboxane A2 receptor
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
L-Tretoquinol (TRETOQUINOL). L-Tretoquinol works by binding to the Beta-1 adrenergic receptor, which is involved in regulating heart rate and blood pressure.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| L-Tretoquinol TARGET | TRETOQUINOL | phase 2 | tretoquinol | Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Thromboxane A2 receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (tretoquinol class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- L-Tretoquinol CI watch — RSS
- L-Tretoquinol CI watch — Atom
- L-Tretoquinol CI watch — JSON
- L-Tretoquinol alone — RSS
- Whole tretoquinol class — RSS
Cite this brief
Drug Landscape (2026). L-Tretoquinol — Competitive Intelligence Brief. https://druglandscape.com/ci/tretoquinol. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing